A study led by Changqun Liu and colleagues investigated the development of novel quinazoline-2-indolinone derivatives as potent and selective PI3Kα inhibitors. Through molecular hybridization and derivatization, a series of compounds were synthesized and evaluated for their antitumor activity. Compound 8, a representative derivative, exhibited strong inhibitory activity against PI3Kα with an IC50 of 9.11 nM and high selectivity compared to other PI3K isoforms. It effectively suppressed the growth of various cancer cell lines, including NSCLC cells, and induced mitochondrial apoptosis via the PI3K/Akt/mTOR pathway. In vivo tests showed that compound 8 significantly inhibited NSCLC progression in mice, outperforming gefitinib. The study highlights the potential of quinazoline-2-indolinone derivatives as promising candidates for PI3Kα-targeted cancer therapy. Compound 8 demonstrated potent in vivo anti-tumor activity without visible toxicity, suggesting its potential as a new therapeutic agent for NSCLC. The research provides a new approach for developing PI3Kα inhibitors and offers insights into the structure-activity relationships of these compounds.A study led by Changqun Liu and colleagues investigated the development of novel quinazoline-2-indolinone derivatives as potent and selective PI3Kα inhibitors. Through molecular hybridization and derivatization, a series of compounds were synthesized and evaluated for their antitumor activity. Compound 8, a representative derivative, exhibited strong inhibitory activity against PI3Kα with an IC50 of 9.11 nM and high selectivity compared to other PI3K isoforms. It effectively suppressed the growth of various cancer cell lines, including NSCLC cells, and induced mitochondrial apoptosis via the PI3K/Akt/mTOR pathway. In vivo tests showed that compound 8 significantly inhibited NSCLC progression in mice, outperforming gefitinib. The study highlights the potential of quinazoline-2-indolinone derivatives as promising candidates for PI3Kα-targeted cancer therapy. Compound 8 demonstrated potent in vivo anti-tumor activity without visible toxicity, suggesting its potential as a new therapeutic agent for NSCLC. The research provides a new approach for developing PI3Kα inhibitors and offers insights into the structure-activity relationships of these compounds.